Trials / Terminated
TerminatedNCT03059888
Trial of Orencia in Patients With Myasthenia Gravis
Pilot Trial of Orencia in Myasthenia Gravis Patients Inadequately Responsive to Conventional Immunotherapy
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 16 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This pilot research study is being done to see if the drug abatacept (Orencia ®) will be helpful in treating patients with myasthenia gravis (MG) who do not respond satisfactorily to other drugs that are used to suppress the immune system. Abatacept has been successful in treating experimental MG in laboratory animals, and this study is to determine its effectiveness in patients with MG.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abatacept Injection | Subcutaneous administration of abatacept |
Timeline
- Start date
- 2017-04-12
- Primary completion
- 2019-07-15
- Completion
- 2019-07-15
- First posted
- 2017-02-23
- Last updated
- 2019-11-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03059888. Inclusion in this directory is not an endorsement.